← Leaderboards
Michael Jay Wagner
Univ Of North Carolina Chapel Hill
$1,178,213
Attributed
$2,356,425
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $716.7K · FY2012–15$1M$750K$500K$250K$0
'12
'13
'14
'15
Funding mix
By agency
NIH$2,356,425 · 1
By mechanism
R01$2,356,425 · 1
Top collaborators
- John B Buse4 shared
Most similar at Univ Of North Carolina Chapel Hill
Same institution · by research overlap
- Victoria Lin Bae-Jump$4,533,215
- Mark H Schoenfisch$13,058,423
- Nobuyo Maeda$24,013,018
- Robert Wirka$1,992,168
- Andrew Stephen Bomback$3,235,628
Others in their field
Top investigators on “Acute”
- Barton F Haynes · Duke University$295,684,085
- Peter C Adamson · National Childhood Cancer Foundation$256,842,224
- Judith S. Currier · University Of California Los Angeles$242,306,415
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$230,305,108
- Lawrence Corey · Fred Hutchinson Cancer Center$204,110,869
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
Research focus
AcuteAdverse OutcomeAffectAdverse EffectsAttributable MortalityBlood GlucoseBlood LipidBlood PressureCandidate Disease GeneAncillary StudyCardiovascular Risk FactorCardiovascular SystemCharacteristicsClinical PracticeClinical TrialsCoupledDiabetes MellitusDiabetic PatientDrug DevelopmentDrug UsageDyslipidemiasEpidemiologic StudiesEventExome
Grant awards (4)
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$363,729
R01 · FY2015 · HL
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$666,552
R01 · FY2014 · HL
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$609,477
R01 · FY2013 · HL
An Exome-Focused Approach to Pharmacogenetic Analysis of the ACCORD Trial$716,667
R01 · FY2012 · HL